Kornimate/medical-research-clean huggingface dataset:
interdisciplinary rehabilitation of patients with glioma during anti-cancer treatment

Conditions: Neoplasms; CNS Neoplasms

Summary: the results of the present rct study will add to the growing body of literature investigating the potential role of exercise as a supportive therapeutic intervention for patient with glioma.

gliomas are the most frequent primary neoplasm in the cns and according to the world health organization histologically categorized into low-grade glioma (lgg) (who grades i/ii) or high-grade glioma (hgg) (who grades iii/iv). gliomas are among the biggest challenges within the field of neuro-rehabilitation and oncology, and optimising treatment by improving qol, function and cognition is of major clinical importance in this population. because the majority of patients cannot be cured, clinical cancer research traditionally have focused on prolonging survival, exposing relapse or optimising the response to the medical treatment. today there is a general consensus that health-related quality of life (hrqol) is important in the evaluation of new treatments. however, research in hrqol among patients with gliomas is scarce compared to the other categories of patients with tumors. in recent years have exercise become an important part of cancer treatment. the effects is well documented in studies among other cancer patients than gliomas and includes improvements of quality of life, physical function, reduce fatigue and thereby supports daily activities among cancer patients'. inpatient rehabilitation studies among glioma patients have also indicated improved hrqol and functional measurements such as activity of daily life, mobility and cognition. despite of this rehabilitation efforts is still not emphasized in this population and recent literature concludes that there are no well-designed clinical studies examining the effect of multidisciplinary rehabilitation among glioma patients. this study is the first to investigate the effect of an intensive specialised interdisciplinary outpatient rehabilitation program among gliomas patients.

Eligibility criteria:
inclusion criteria: * diagnosis of primary glioma (who grades i-iv) * age ≥ 18 * reference with diagnosis or treatment at odense university hospital * karnofsky performance score (kps) ≥70 * ability to understand danish. exclusion criteria: * pregnancy * known psychiatric diagnosis or substance abuse * heart problems excluding intense exercise (nyha group iii and iv) * pronounced impressive/expressive aphasia

Keywords: interdisciplinary rehabilitation neurooncology physiotherapy occupational therapy neurorehabilitation glioma
evolving methods of hybrid exercise-cognition approach to promote health-related conditions for the elderly with mci

Conditions: Mild Cognitive Impairment; Stroke

Summary: the aim of the study is to determine: (1) the effects of combined physical exercise and cognitive training versus exercise or cognitive training alone on cognition, physical function, daily function, quality of life and social participation outcomes, (2) determine the relative effects of simultaneous vs. sequential combination of physical exercise and cognitive training on these health-related outcomes, (3) determine the long-term effects of different types of trainings on these outcome measures.

mild cognitive impairment (mci) or minor neurocognitive disorder involves problems with memory, executive function and language. the age-adjusted prevalence of mci in taiwan is approximately 18%. the progression rate from mci to dementia ranges from 10 to 15% each year, and over 50% of the mci population will develop into severe cognitive impairment or dementia in five years. early detection and intervention of the individuals with mci may help delay or prevent progress from mci to dementia, and reduce the burden of their caregivers and the medical expenses of the health-care system. whilst numerous studies have established the potential benefits of cognitive or physical exercise training on cognition for individuals with mci, some recent studies suggested that combining physical exercise and cognitive training may augment the intervention effects. also, different combination methods - combining physical exercise and cognitive training either sequentially or simultaneously under a dual-task paradigm may impose differential cognitive challenges on the participants, and it is yet not clear which combination strategy has better training effects.

Eligibility criteria:
inclusion criteria: * able to follow instruction, * age 55 to 90 years old, * clinical dementia rating (cdr) = 0.5 or 1, * self- or informant-reported memory or cognitive complaints, * able to perform activities of daily living (barthel index ≥ 70). exclusion criteria: * participants will be excluded if they have recent myocardial infarction, heart failure, recent heart surgery, severe asthma, concomitant with other neurological disorders, or joint deformity that might prevents them performing exercise or cognitive training.

Keywords: aerobic exercise cognitive training hybrid therapy
health benefits of tart cherry in crohn's disease

Conditions: Crohn Disease (CD)

Summary: crohn's disease (cd) is a long-term inflammatory condition of the digestive tract. people with cd often experience unpredictable and debilitating symptoms, including abdominal pain, diarrhea, and fatigue. additionally, they require long-term treatment, which is often associated with frequent negative effects, the need for surgery, and hospitalizations. as a result, individuals with cd report a lower health-related quality of life (hrqol) compared to healthy individuals. the most common medication for inflammatory bowel disease is a strong immunosuppressant, which was identified in 2017 as the most expensive medication prescribed in nhs hospitals. unfortunately, biologics have significant side effects, and reducing the reliance on them could benefit both the nhs by lowering costs and patients by minimizing unwanted side effects. supplementation with montmorency tart cherry juice may offer a simple, safe, and cost-effective intervention for improving symptoms in individuals with cd. this is due to its potential to naturally reduce inflammation in the digestive system, thereby alleviating symptoms. research in animal models has shown potential improvements in physiological responses with similar supplements, including blueberries, black raspberries, and montmorency tart cherries, though only one study in human participants has explored bilberry supplementation. despite montmorency tart cherries having superior anthocyanin concentrations compared to other berries, dietary interventions using tart cherry supplementation for cd have not been explored in human participants. the primary aim of the proposed investigation is to conduct a placebo-controlled randomized trial to examine whether montmorency tart cherry juice supplementation can provide symptom relief and improve health-related well-being in individuals with mild to moderately active cd, as well as to understand the biological mechanisms underlying any observed symptom changes.


Eligibility criteria:
inclusion criteria: * an established diagnosis of cdfor at least 6 months * current mild to moderate disease activity * age between 18 and 65 years * stable use of medication for at least 3 months respectively. exclusion criteria: * diabetes * hiv * hepatitis b and c infection * abscesses * unstable medical conditions that would likely prevent the subject from completing the study * food allergies to cherries.
efficacy and safety of daxibotulinumtoxina (daxi) for injection for treatment of upper facial lines

Conditions: Upper Facial Lines (Glabellar Lines, Forehead Lines, & Lateral Canthal Lines)

Summary: this is a phase 2, multicenter, open-label, single-arm study to evaluate the efficacy and safety of daxibotulinumtoxina for injection (daxi for injection) in the treatment of glabellar lines (gl), dynamic forehead lines (fhl), and lateral canthal lines(lcl)


Eligibility criteria:
inclusion criteria: 1. provide written informed consent consistent with international conference on harmonisation-good clinical practice (ich-gcp) guidelines and local laws, including authorization to release health information, signed prior to any study procedures being performed 2. be outpatient, male or female subjects, in good general health, 18 years of age or older 3. have a score of moderate (2) or severe (3) glabellar lines during maximum contraction as assessed by the investigator global assessment-frown wrinkle severity (iga-fws) and patient frown wrinkle severity (pfws) 4. have a score of moderate (2) or severe (3) forehead lines during maximum contraction as assessed by the investigator global assessment forehead wrinkle severity (iga-fhws) and patient forehead wrinkle severity (pfhws) 5. have a score of moderate (2) or severe (3) lateral canthal lines at maximum contraction as assessed by the investigator global assessment of lateral canthal wrinkle severity (iga-lcws) and patient lateral canthal wrinkle severity (plcws) (scores must be consistent bilaterally for each scale considered separately) 6. able to understand the requirements of the study and be willing and able to follow all study procedures, attend all scheduled visits, comprehend and complete the questionnaires without outside assistance and successfully complete the study exclusion criteria: 1. active skin disease, infections, or inflammation at the injection sites 2. planned or anticipated need for surgery or hospitalization through the end of the study 3. pregnant, nursing, or planning a pregnancy during the study; or is a women of child bearing potential (wocbp) but is not willing to use an effective method of contraception 4. current enrollment in an investigational drug or device study or participation in such a study within the last 30 days prior to screening

Keywords: lateral canthal wrinkle crow's feet lines lcl forehead lines glabellar lines frown lines upper facial lines
pharmacogenetics study on the effects of anesthetic drugs on circulatory function

Conditions: Drug Reaction; Anesthetic; Hemodynamic Rebound; Gene

Summary: this study intends to study the effects of anesthetics on circulatory function genomics and find the anesthetic effects in pharmacodynamics, pharmacokinetics, drug receptor or target dna level differences, further guiding individual treatment in clinic, promoting the development of precision the medicine.the anesthesia medication during perioperative period is more and more accurate,reasonable and safe, so as to improve the satisfaction of the patients and their families in the perioperative period, to ensure the safety of patients.

this study is a non traumatic and non intervention study, and will use a large sample of clinical research, the number of subjects to be enrolled in the study group are 200 cases. the basic information of the study was included in the study before the operation. during the operation, the investigators need a collection of participants's arterial blood and monitor the hemodynamic index and anesthesia depth by bispectral index(bis) . further more，the investigators will follow up the participants' condition after operation.dividing the patients into different groups according to their clinical features.the relationship between vital signs and the depth of anesthesia was analyzed and compared between different groups.blood samples collected during the operation were detected by gene test. comparing the results of genetic testing and clinical data analysis, then the investigators will find the differences in the expression of the gene polymorphisms of anesthetic drugs in the circulating function.

Eligibility criteria:
inclusion criteria: * undergoing general anesthesia * undergoing cardiovascular surgery exclusion criteria: * asa granding more than five * severe organ dysfunction

Keywords: personalized medicine genetic polymorphism pharmacogenetics hemodynamic change
pilot study of 18f-fmiso pet/ct and mri imaging to explore tissue hypoxia and arteriovenous shunting in subjects with recurrent glioblastoma before and after bevacizumab treatment

Conditions: Recurrent Glioblastoma

Summary: subjects with recurrent glioblastoma who are candidates for bevacizumab treatment according to standard of care will be eligible for this study. positron emission tomography (pet/ct) imaging will use the investigational radiotracer \[18f\]fmiso to image the brain and evaluate for hypoxia pre and post therapy.. subjects will also undergo up to three brain mris.


Eligibility criteria:
inclusion criteria: * participants will be ≥ 18 years of age * biopsy proven glioblastoma * must meet one of the following criteria: * recent surgery (within 2 months) showing recurrent glioblastoma with measurable (20 mm in 2 dimensions) residual tumor. radiologic evidence of recurrent tumor based on conventional and advanced mri findings. * recommended for clinically indicated bevacizumab therapy * life expectancy of greater than 3 months in the opinion of an investigator or treating physician. * karnofsky performance status ≥ 60 * participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures. exclusion criteria: * inability to tolerate imaging procedures in the opinion of an investigator or treating physician * females who are pregnant or breast feeding at the time of screening will not be eligible for this study; a urine pregnancy test will be performed in women of child-bearing potential at screening. * any current medical condition, illness, or disorder as assessed by medical record review and/or self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study * less than 3 months from finishing the most recent radiation or immunotherapy. * contraindications to mri or use of gadolinium contrast * only individuals (aged 18 or over) who can understand and give informed consent will be approached to participate in this study. individuals who are considered to be mentally disabled will not be recruited for this study. all subjects must understand and be able to give informed consent. we will not be using specific methods to assess decisional capacity. economically disadvantaged persons will not be vulnerable to undue influence, as this study offers no compensation. all individuals will be told that their choice regarding study participation will in no way change their access to clinical care. this should negate any undue influence or coercion. pregnant women, children, fetuses, neonates, or prisoners are not included in this research study.
follow-up of a cohort of patients with aortic valve bicuspidia

Conditions: Aortic Valve, Bicuspid

Summary: the aortic valve bicuspidia (bva) is a congenital condition corresponding to the presence of 2 sigmoids instead of 3. this is the most common cardiac congenital anomaly affecting 0.5 to 2% of the population the general rule. bva may be associated with structural damage to the ascending aorta, which exposes bva patients to a risk of developing ascending aortic aneurysm and acute aortic accidents. recent data from the literature have revealed that the natural history of bva is marked by a possible development towards significant valvulopathy and / or an ascending aortic aneurysm often requiring surgical treatment. however, the natural history of bicuspid disease remains poorly understood and the prognostic factors for progression to severe valvulopathy and / or aneurysmal dilatation of the ascending aorta remain to be determined.


Eligibility criteria:
inclusion criteria: * all patients examined in the echocardiography laboratory whose objective examination was a bicuspid valve of the aortic valve * bicuspidia may be formerly known exclusion criteria: * refusal to participate * patients who had already undergone bicuspid surgery or ascending aorta before being examined at the echocardiography laboratory
neurocognitive and neurobiological improvement in adhd children by modification of dietary protein

Conditions: ADD; ADHD

Summary: multicenter, prospective, randomized, comparative and controlled study about the beneficial effects in behavior and brain connectivity of different dietary patterns in 100 children with adhd between 7 and 12 years, followed up for 3 months of nutritional therapy.

the investigators collect electroencephalogram (eeg), event related potentials (erp) data, and behavior parameters in add/adhd children that not take stimulants or other drugs during study. they would only follow some nutritional recommendations based on increasing the amount of dietary protein and fast carbohydrates decrease. the duration of the study will be 6 months, 3 months for recruitment and 3 months for dietary treatment.

Eligibility criteria:
inclusion criteria: * adhd diagnosed 12 months before * no take medication * bmi above the 25th percentile * wiesel score between 80 and 100 (about 120) * patients who agree to participate and whose guardians signed the informed consent form exclusion criteria: * eating disorders * psychosis, bipolar disorder or depression * kidney or liver failure * diabetes * diuretic or cortisone treatment * haematological problems * suprarenal diseases * cancer * brain injury * cardiovascular or arrhythmia problems

Keywords: add adhd proteins dietary nutrition qeeg erp ica
study of pain catastrophizing

Conditions: Osteo Arthritis Knee

Summary: this study proposes to experimentally manipulate pain catastrophizing in order to investigate the neural mechanisms by which pain catastrophizing influences the experience of pain among non-hispanic blacks (nhbs) and non- hispanic whites (nhws) with knee osteoarthritis (oa). therefore, participants will be randomized to either a single session cognitive-behavioral intervention to reduce pain catastrophizing or a pain education control group.


Eligibility criteria:
inclusion criteria: * symptomatic knee oa exclusion criteria: * younger than 45 years of age or older than 85 years of age * prosthetic knee replacement or other clinically significant surgery to the arthritic knee * uncontrolled hypertension (\>150/95) * heart disease including heart failure * peripheral neuropathy in which pain testing was contraindicated * systemic rheumatic disorders including rheumatoid arthritis, systemic lupus erythematosus, gout, and fibromyalgia * neurological diseases such as parkinson's, multiple sclerosis, stroke with loss of sensory or motor function, or uncontrolled seizures * significantly greater pain in body sites other than in the knee * daily opioid use * hospitalization within the preceding year for psychiatric illness * currently pregnant or nursing/breastfeeding

Keywords: catastrophizing cognitive-behavior therapy
correlation between thermal patterns of infrared thermal imaging and clinical phenotype in patients with postherpetic neuralgia

Conditions: Postherpetic Neuralgia; Infrared Thermal Imaging

Summary: postherpetic neuralgia (phn) is the most frequent complication of herpes zoster(hz) and is defined as pain persisting for \>1month after the healing of herpetic skin lesion or pain persisting for \> 3 months following the onset of hz. phn manifests as spontaneous throbbing, stabbing, or burning, usually accompanied by various abnormal sensory symptoms , which affect 5-20% of patients with hz. due to the lack of accurate and objective auxiliary examination tools, it is difficult for diagnosis and treatment of phn. as a non-invasive examination method, infrared thermal imaging (irt) can play a role in the diagnosis and treatment of neuropathic pain by objectively reflecting the changes and distribution characteristics of human body surface temperature. however, there are few studies on the relationship between clinical phenotype and thermal infrared image temperature changes in phn patients, and the relationship between the thermal pattern of skin temperature and the duration of disease and treatment progress in phn patients has not been fully elucidated. this study was conducted to investigate the relationship of thermal imaging data with the duration of the disease, clinical phenotype, treatment effect, in order to explore the role of infrared thermal imaging in the diagnosis and treatment of phn. methods：all phn patients will included. at each visit, a pain nrs score was performed, and clinical phenotypes were tested and labeled, including: allodynia, numbness, itching, heat sensation, cold sensation, and the most painful area(mpa). infrared thermal imaging was performed, the average relative temperature (art) within the affected area and the contralateral area was compared. the relationship between the temperature change and duration of the disease, clinical phenotype, treatment effect was assessed.

patients with the follow conditions were excluded: 1)the skin area was lesions because of other disease(trauma, inflammation, skin scar, skin disease, tumor, etc.); 2) history of psychiatric diseases, chronic pain. 3) inabilities to complete irt examination.

Eligibility criteria:
inclusion criteria: * 1) patients\>18 years-old 2) pain lasts at least 1 month after lesion crusting 3) agreed to participate the research exclusion criteria: * 1))the skin area was lesions because of other disease(trauma, inflammation, skin scar, skin disease, tumor, etc.); 2) history of psychiatric diseases, chronic pain. 3)inabilities to complete irt examination. 4) disagree to participate to the research

Keywords: postherpetic neuralgia infrared thermal imaging clinical phenotype disease course
clinical trial to evaluate the efficacy, safety, and tolerability of ro7239361 in ambulatory boys with duchenne muscular dystrophy

Conditions: Duchenne Muscular Dystrophy

Summary: this is a multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of two different weekly doses of ro7239361 in ambulatory boys with duchenne muscular dystrophy (dmd).


Eligibility criteria:
inclusion criteria: * diagnosed with dmd by confirmed medical history and genetic testing * able to walk without assistance * minimum north star ambulatory assessment score of 15 at screening * able to walk up 4 stairs in 8 seconds or less * weigh at least 15 kg (33 lbs) * taking corticosteroids for dmd exclusion criteria: * any behavior or mental issue that will affect the ability to complete the required study procedures * previously or currently taking medications like androgens or human growth hormone * use of a ventilator during the day * unable to have blood samples collected or receive an injection under the skin * concomitant or previous participation at any time in a gene therapy study other protocol defined inclusion/exclusion criteria could apply.

Keywords: muscular dystrophy duchenne's muscular dystrophy dmd